Trials / Completed
CompletedNCT05298449
Phase 2 of HU-045 in Glabellar Lines
A Multicenter, Double-blind, Randomized, Parallel, Active-controlled, Phase II Clinical Trial to Evaluate the Efficacy and Safety of HU-045 and Xeomin® in Patients With Moderate to Severe Glabellar Lines
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 50 (actual)
- Sponsor
- Huons Co., Ltd. · Industry
- Sex
- All
- Age
- 19 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
A Multicenter, Double-blind, Randomized, Parallel, Active-controlled, Phase II Clinical Trial to Evaluate the Efficacy and Safety of HU-045 and Xeomin® in Patients With Moderate to Severe Glabellar Lines
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | HU-045 | HU-045 is a medicine that is injected into muscles and used to improve the look of moderate to severe frown lines between the eyebrows (glabellar lines) in adults for a short period of time (temporary). It should be reconstituted with sterile, preservative-free 0.9% saline before use. White powder |
| DRUG | Xeomin® | Xeomin® is a prescription medicine that is injected into muscles and used to improve the look of moderate to severe frown lines between the eyebrows (glabellar lines) in adults for a short period of time (temporary). It should be reconstituted with sterile, preservative-free 0.9% saline before use. |
Timeline
- Start date
- 2022-03-28
- Primary completion
- 2022-11-07
- Completion
- 2023-04-25
- First posted
- 2022-03-28
- Last updated
- 2023-07-05
Locations
1 site across 1 country: South Korea
Source: ClinicalTrials.gov record NCT05298449. Inclusion in this directory is not an endorsement.